Status:
COMPLETED
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Abbott
Conditions:
Insulin Resistance
Hypertriglyceridemia
Eligibility:
All Genders
30-65 years
Phase:
NA
Brief Summary
Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and...
Detailed Description
It has been estimated that approximately ¼ of the US population has the Insulin Resistant Syndrome (IRS). The notion that insulin resistance and compensatory hyperinsulinemia lead to a cluster of abno...
Eligibility Criteria
Inclusion
- Insulin Resistant Triglyceride 150 mg/dL or greater or triglyceride HDL-C ratio 3 or greater BMI 25-35
Exclusion
- Diabetes Mellitus History of gall stones History of CHF History of CAD Severe anemia,kidney, or liver disease
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00186537
Start Date
September 1 2003
End Date
September 1 2008
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Medical Center
Stanford, California, United States, 94305